Novartis Pharma AG: Novartis shares Zolgensma long-term data demonstrating sustained durability up to 7.5 years post-dosing; 100% achievement of all assessed milestones in children treated prior to SMA symptom onset

Children in LT-001 treated after SMA symptom onset maintained or achieved additional milestones up to 7.5 years post one-time intravenous infusionAll children (100%) in the presymptomatic intravenous cohort

Related Keywords

London ,City Of ,United Kingdom ,United States ,Switzerland ,America ,Sitra Tauscher Wisniewski ,Intrathecal Onasemnogene Abeparvovec ,Richard Jarvis ,Isabella Zinck ,Michael Meo ,Satoshi Sugimoto ,Nicole Zinsli Somm ,Jerryr Mendell ,Samir Shah ,Parag Mahanti ,Julie Masow ,Sloan Simpson ,Mary Carmichael ,Onasemnogene Abeparvovec ,Exchange Commission ,Muscular Dystrophy Association ,Clinical Development Analytics ,Academic Press Elsevier ,Twitter ,Novartis ,Long Term Follow Up ,Dystrophy Association ,Scientific Conference ,Nationwide Children ,Vice President Clinical Development ,Novartis Gene ,Term Follow Up ,Gene Therapies ,Accessed February ,Onasemnogene Abeparvovec Gene Therapy ,Asymptomatic Patients ,Spinal Muscular Atrophy Type ,Intrathecal Onasemnogene Abeparvovec Gene Therapy ,Presymptomatic Spinal Muscular Atrophy ,Spinal Muscular Atrophy ,Muscular Atrophy ,Disease Mechanisms ,Diese Gold Aktie ,Sichern Sie ,Dharma ,Hares ,Zolgensma ,Song ,Term ,Data ,Emonstrating ,Sustained ,Durability ,Tears ,Most ,Closing ,Achievement ,Zpossessed ,Ilestones ,Children ,Reated ,Rior ,Symptom ,Onset ,